Evaluation of albutoin as an antiepileptic drug.
D000293:Adolescent; D000328:Adult; D000498:Allyl Compounds / Q000009:adverse effects / Q000097:blood / Q000627:therapeutic use; D000704:Analysis of Variance; D000927:Anticonvulsants / Q000009:adverse effects / Q000097:blood / Q000627:therapeutic use*; D001066:Appetite / Q000187:drug effects; D001702:Biopharmaceutics; D002855:Chromatography, Thin Layer; D002986:Clinical Trials as Topic; D004341:Drug Evaluation; D004828:Epilepsies, Partial / Q000188:drug therapy; D004827:Epilepsy / Q000188:drug therapy*; D004833:Epilepsy, Temporal Lobe / Q000188:drug therapy; D005260:Female; D006801:Humans; D006827:Hydantoins / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced; D010634:Phenobarbital / Q000627:therapeutic use; D010672:Phenytoin / Q000627:therapeutic use; D010919:Placebos; D011324:Primidone / Q000627:therapeutic use; D013053:Spectrophotometry; D013223:Statistics as Topic; D013867:Thiohydantoins / Q000009:adverse effects / Q000097:blood / Q000627:therapeutic use; D013997:Time Factors; D014839:Vomiting / Q000139:chemically induced
D000498:Allyl Compounds; D000927:Anticonvulsants; D006827:Hydantoins; D010919:Placebos; D013867:Thiohydantoins; D011324:Primidone; D010672:Phenytoin; D010634:Phenobarbital